ReviewProstate cancer2013
Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.
Review in Prostate cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- miR-455-3p has superior diagnostic potential to PSA in peripheral blood for prostate cancer.PloS one · 2025Article
- Identification and functional analysis of LncRNA-XIST ceRNA network in prostate cancer.BMC cancer · 2022Article
- Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE.Journal of bone oncology · 2021Article
- Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease.Frontiers in endocrinology · 2021Article
- Integrated approach to pain management for a patient with multiple bone metastases of uterine cervical cancer.The Journal of international medical research · 2018Article
- Current approaches to incorporation of radium-223 in clinical practice.Prostate cancer and prostatic diseases · 2018Review
- Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.Frontiers in oncology · 2018Review
- The Relationship of Industry Payments to Prescribing Behavior: A Study of Degarelix and Denosumab.Urology practice · 2017Article
- Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progression.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2016Review
- Radium-223 dichloride in clinical practice: a review.European journal of nuclear medicine and molecular imaging · 2016Review
- Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.Clinical Medicine Insights. Oncology · 2016Review
- Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.European urology · 2015Article
- Targeting bone metastases in prostate cancer: improving clinical outcome.Nature reviews. Urology · 2015Review
- Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review.BoneKEy reports · 2015Review
- XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).Journal of hematology & oncology · 2014Article
- Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union.Health and quality of life outcomes · 2014Article
- Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.Therapeutics and clinical risk management · 2014Review
- Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis.American journal of clinical and experimental urology · 2013Review
- Health-Related Quality-of-Life Outcomes with Actinium-225-Prostate-Specific Membrane Antigen-617 Therapy in Patients with Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs. Bisphosphonates were the first class of drugs investigated for prevention of SREs and zoledronic acid is the only bisphosphonate that is FDA-approved for this indication. Another bone-targeted agent is denosumab which is a fully humanized monoclonal antibody that binds to the RANK-L thereby inhibiting RANK-L mediated bone resorption. While several radiopharmaceuticals were approved for pain palliation in mCRPC including strontium and samarium, alpharadin is the first radiopharmaceutical to show significant overall survival benefit. Contemporary therapeutic options including enzalutamide and abiraterone have effects on pain palliation and SREs as well. Other novel bone-targeted agents are currently in development, including the receptor tyrosine kinase inhibitors cabozantinib and dasatinib. Emerging therapeutics in mCRPC has resulted in great strides in preventing one of the most significant sources of complications of bone metastases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.